Open original FDA record ↗Recall record
- FDA identifier
- Z-0422-2022
- Company in FDA record
- Biomerieux Inc
- FDA record creation date
- Dec 27, 2021
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
There is an error in the new version of the package insert. The Reading Table lists the incorrect color for a negative result for the CIT test.
Source facts
- Action
- bioMerieux in the U.S. issued an Urgent Field Safety Notice dated November 2021 on 11/9/2021 via email for delivery to the Lab Director or Lab Manager. The notice described the issue, impact to the customer, and listed the required customer actions: Distribute the information to all appropriate personnel in their laboratory and forward the information to all parties that may use the product, including others to whom the product may have been transferred. The customer is informed they can continue to use RAPID 20 E, however, they must refer to the following Reading Table or to the corrected RAPID 20 E package insert version "G1" available on Resource Center when reading the CIT test result. For tests previously performed using RAPID 20 E, the customer is strongly recommended that they identify any possible misidentifications to analyze the related risks and to determine appropriate actions, if relevant. An Acknowledgement Form was enclosed to confirm receipt of the notice.
- Initiated
- 2021-11-09
- Root cause
- Under Investigation by firm
- Terminated
- 2025-02-10
- Distribution
- US Nationwide distribution in the states of AL, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IL, IN, KS, KY, MA, MI, MO, NC, NE, NJ, NY, OH, OK, PA, RI, SC, SD, TX, VA, WA, and WI. There was government distribution but no military distribution.
- Recall number
- Z-0422-2022
- Recall status
- Terminated
- CDRH record ID
- 190365
- FDA record created
- 2021-12-27
- Recall event number
- 89041